Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Keeps “Buy” Rating at Truist Financial

Truist Financial reiterated their buy rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) in a report published on Wednesday,Benzinga reports. Truist Financial currently has a $743.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $709.00.

A number of other brokerages have also recently weighed in on MDGL. Barclays reduced their price target on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. The Goldman Sachs Group assumed coverage on shares of Madrigal Pharmaceuticals in a research report on Thursday, September 24th. They set a “buy” rating and a $704.00 price target for the company. Canaccord Genuity Group increased their price target on Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. HC Wainwright reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 31st. Finally, Wolfe Research upgraded Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price objective on the stock in a research note on Tuesday, August 4th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $706.87.

Madrigal Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ MDGL opened at $400.43 on Wednesday. The stock has a market capitalization of $9.25 billion, a PE ratio of -66.96 and a beta of -0.98. The company has a quick ratio of 2.94, a current ratio of 3.20 and a debt-to-equity ratio of 0.65. The firm has a fifty day moving average of $492.40 and a 200-day moving average of $498.45. Madrigal Pharmaceuticals has a 52-week low of $353.54 and a 52-week high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating the consensus estimate of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative return on equity of 27.93% and a negative net margin of 10.89%. The business had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. During the same period in the previous year, the company posted ($5.08) EPS. On average, analysts anticipate that Madrigal Pharmaceuticals will post -7.03 EPS for the current year.

Insider Transactions at Madrigal Pharmaceuticals

In other news, CEO William Sibold sold 6,362 shares of Madrigal Pharmaceuticals stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $535.59, for a total transaction of $3,407,423.58. Following the sale, the chief executive officer directly owned 202,967 shares of the company’s stock, valued at approximately $108,707,095.53. The trade was a 3.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon T. Kelley sold 664 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $514.97, for a total value of $341,940.08. Following the completion of the transaction, the general counsel owned 11,474 shares in the company, valued at approximately $5,908,765.78. This trade represents a 5.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 12,247 shares of company stock valued at $6,581,182. 17.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Jupiter Topco LLC acquired a new position in Madrigal Pharmaceuticals in the second quarter worth about $1,039,650,000. Paulson & CO. Inc. bought a new stake in Madrigal Pharmaceuticals in the second quarter valued at about $719,524,000. BlackRock Inc. acquired a new stake in Madrigal Pharmaceuticals during the second quarter valued at approximately $644,753,000. Janus Henderson Group PLC raised its stake in Madrigal Pharmaceuticals by 27.4% during the first quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company’s stock valued at $1,051,727,000 after buying an additional 433,804 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new position in Madrigal Pharmaceuticals during the 2nd quarter worth approximately $174,038,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Madrigal Pharmaceuticals News Roundup

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Q3 results substantially beat expectations. Madrigal reported earnings of $1.83 per share, versus the consensus estimate of a $1.09 loss, and revenue of $431.3 million, ahead of the $404.2 million estimate. Rezdiffra sales growth helped drive the results, with coverage reporting sales surpassed $1 billion. Madrigal Q3 results
• Positive Sentiment: Analysts raised price targets and maintained Buy ratings. Canaccord lifted its target to $633 from $612, Truist to $743 from $709, and Citi to $760 from $725. The upgrades reflect substantial potential upside, though targets are analysts’ estimates, not guarantees. Canaccord rating Truist rating Citi rating
• Neutral Sentiment: Clinical development continues, but key data are not imminent. Madrigal expects the MAESTRO-NASH OUTCOMES readout in late 2027 and is planning a 2,000-plus-patient MAESTRO-CSPH study. These programs offer longer-term potential, but their timelines mean they are less likely to provide a near-term catalyst. Madrigal clinical plans
• Negative Sentiment: Legal investigations and profit-sustainability questions remain risks. Two law firms announced investigations into potential securities-law violations; these are allegations under investigation, not findings of wrongdoing. Separate coverage cited investor concerns about near-term profitability, which could temper the reaction to the strong quarterly beat. Kirby McInerney investigation notice Kaplan Fox investigation notice

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.